Objective: The present study examined the efficacy, safety, and durability of repeated ketamine infusions for the treatment of comorbid posttraumatic stress disorder (PTSD) and treatment-resistant depression (TRD) in a sample of veterans. Methods: Individuals with comorbid DSM-5-defined PTSD and DSMIV- defined major depressive disorder (N = 15) received 6 intravenous ketamine infusions (0.5 mg/kg) on a Monday-Wednesday-Friday schedule over a 12-day period from May 2015 to June 2016. Data from outcome measures were collected before and 24 hours after each infusion and weekly for 8 weeks following the final infusion. Results: Continuous measures of symptom change were significant for both disorders and were associated with large effect sizes (mean decrease in PTSD Checklist for DSM-5 score = 33.3 points [95% CI, 23.0-43.5 points], P < .0005, sample size-adjusted Cohen d [d'] = 2.17; mean decrease in Montgomery-Asberg Depression Rating Scale score = 26.6 points [95% CI, 23.0-30.2 points], P < .0005, d'= 4.64). The remission rate for PTSD was 80.0%, and the response rate for TRD was 93.3%. Participants in remission from PTSD after the infusion series (n = 12) had a median time to relapse of 41 days. Similarly, participants whose depression symptoms responded to the infusion series (n = 14) had a median time to relapse of 20 days. Repeated ketamine infusions were associated with transient increases in dissociative symptoms. No participant reported worsening of PTSD symptoms over the study duration. Conclusions: This study, the first open-label study of repeated ketamine infusions in a comorbid population, found rapid and sustained improvement in PTSD and depression symptoms. This report suggests that repeated ketamine treatments are safe and may represent an efficacious treatment for individuals with comorbid PTSD and TRD.
|Original language||English (US)|
|Journal||Journal of Clinical Psychiatry|
|State||Published - May 1 2018|
Bibliographical noteFunding Information:
Submitted: April 5, 2017; accepted October 17, 2017. Published online: May 1, 2018. Potential conflicts of interest: Drs Albott, Lim, Forbes, Erbes, Tye, Grabowski, Thuras, Wels, and Shiroma and Ms Batres-y-Carr report no financial or other relationship relevant to the subject of this article. Funding/support: This research was supported by the Mental Health Service Line at the Minneapolis VA Health Care System. Drs Albott and Forbes are supported by a Training Award (T320A037183) from the National Institute on Drug Abuse. Dr Shiroma receives support from the Veterans Health Administration Office of Research and Development, Clinical Science Research and Development Merit Review Award for Clinical Trials.
© Copyright 2018 Physicians Postgraduate Press, Inc.